aged 70-80 or younger (but with poor ECOG PS) received a CBDCA + VP16 treatment, at a 4-week interval as follows: cycle 1: CBDCA = AUC 4; VP16 = 50 mg b.i.d. orally d 1-14); cycle 2: CBDCA = AUC 5; VP16 = 50 mg b.i.d. orally d 1-14; cycle 3: CBDCA = AUC ...
Hexamethylmelamine (HMM) and oral etoposide (VP-16) have shown to be active against platinum-resistant epithelial ovarian cancer. On this basis a three-drug regimen including carboplatin (CBDCA) plus HMM and oral VP-16 was tested in previously untreated ovarian cancer patients with tumor size &...
Lung Cancer Volume 11, Supplement 1, June 1994, Pages 101Abstract Therapy Chemotherapy/Small cellDose escalation study of carboplatin (CBDCA) and etoposide (VP-16) with G-CSF in small cell lung cancer (SCLC) : N. Katakami∗, M. Okazaki∗, Y. Ariyoshi, H. Ikegami, K. Furuse, M. ...
We have reported the efficacy of the salvage chemotherapy P-IMVP16/CBDCA for patients with diffuse large B cell lymphoma (DLBCL) who had previously received CHOP before the availability of rituximab (R). Here, we confirmed the efficacy of R combined with P-IMVP16/CBDCA as a salvage ...
IMVP‐16aggressive non‐Hodgkin's lymphomarelapsed lymphomarefractory lymphomaThe purpose of this study was to determine the efficacy of salvage chemotherapy with, P-IMVP-16/CBDCA, consisting of carboplatin (CBDCA), etoposide (VP-16), ifosfamide (IFM), and methotrexate (MTX), for patients with ...
The 45 consecutively enrolled patients received methylprednisolone (mPSL) 1000 mg per body for 3 d (from day 1 to day 3), IFM 1000 mg/m2 for 5 d (from day 1 to day 5), MTX 30 mg/m 2 on day 3 and day 10, VP-16 80 mg/m 2 for 3 d (fro...
Carboplatin (CBDCA) plus etoposide (VP-16) in non small cell lung cancer (NSCLC) treatment - European Journal of Cancerdoi:10.1016/0959-8049(93)91532-PBernardo, G.Bernardo, A.Plastina, M.Strada, M.R.Brunetti, G.Pozzi, U.Rossi, A....
243 A phase II study of the recombinant human interleukin 3 (IL-3) following carboplatin (CBDCA) and etoposide (VP-16) chemotherapy in patients with small cell lung cancer (SCLC)doi:10.1016/0959-8049(95)95501-VTo evaluate the safety and the efficacy of IL-3 (Sandoz), SCLC patients (pts...
--> Abstract: The purpose of this study was to determine the efficacy of salvage chemotherapy with, P‐IMVP‐16/CBDCA, consisting of carboplatin (CBDCA), etoposide (VP‐16), ifosfamide (IFM), and methotrexate (MTX), for patients with aggressive non‐Hodgkin's lymphoma (NHL) who had ...
Tandem high-dose (HD) chemotherapy (CT) with VP-16, ifosfamide (IFM), and carboplatin (CBDCA) with autologous bone marrow transplantation (ABMT) for patients (PTS) with germ-cell tumors (GCT) or gestational trophoblastic disease (GTD)